infants – Medxy AI

Nirsevimab Cuts RSV Lower Respiratory Infections in Infants Without Replacing Other Viruses: Post‑hoc Analysis of the Phase 3 MELODY Trial

By MedXY 11/10/2025

Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory pathogens.

Infectious Diseases news Pediatrics

Mass Azithromycin Administration in Malian Infants Shows No Mortality Benefit: A Large-Scale Randomized Trial

By MedXY 10/25/2025

A large randomized trial in Mali demonstrated that mass azithromycin administration to infants aged 1–11 months did not reduce mortality compared to placebo, challenging previous findings in sub-Saharan Africa.

Pediatrics Public Health Respiratory Specialties

Understanding RSV: Why Immunization Is a Game-Changer for Infants and Vulnerable Adults

By MedXY 09/29/2025

Respiratory Syncytial Virus (RSV) poses serious risks to infants and older adults. Since 2023, RSV immunizations have drastically reduced hospitalizations and deaths. This article explains RSV, symptoms, immunization options, and prevention strategies.

Pediatrics Public Health Specialties

Promising Immunogenicity and Safety of the Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers

By MedXY 08/28/2025

This phase I/II trial demonstrates that the live-attenuated intranasal RSV vaccine (RSVt) is immunogenic and well-tolerated in infants and toddlers, offering a potential new preventive option against RSV infection.